Euroopan unioni - suomi - EMA (European Medicines Agency)

biopartners gmbh - recombinant human interferon alfa-2a - hepatiitti c, krooninen - immunostimulantit, - adult patients with histologically proven chronic hepatitis c who are positive for hepatitis c virus (hcv) antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation. the efficacy of interferon alfa-2a in the treatment of hepatitis c is enhanced when combined with ribavirin. alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.

Euroopan unioni - suomi - EMA (European Medicines Agency)

biomarin international limited - recombinant human n-acetylgalactosamine-6-sulfatase - muukopolysakkaridoosi iv - muut ruuansulatuselimistön sairauksien ja aineenvaihduntasairauksien lääkkeet, - vimizim on tarkoitettu hoito mucopolysaccharidosis, kirjoita iva (morquion a oireyhtymä, mps iva) potilaiden kaikenikäisille.

Euroopan unioni - suomi - EMA (European Medicines Agency)

sanofi b.v. - tirotropiini alfa - kilpirauhasen vajaatoiminta - anterior aivolisäkkeen etulohkon hormonit ja analogit, aivolisäkkeen ja hypotalamuksen hormonit sekä analogit - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.

Euroopan unioni - suomi - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - rokotteet - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Euroopan unioni - suomi - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. käyttö tämä rokote tulee virallisten suositusten mukaisesti. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Euroopan unioni - suomi - EMA (European Medicines Agency)

unigene uk ltd. - recombinant salmon calcitonin - hypercalcemia; osteitis deformans; bone resorption - kalsiumin homeostaasi - kalsitoniini on tarkoitettu:ehkäisy akuutista immobilisaatiosta johtuva äkillinen luukato, kuten potilailla, joilla on recentosteoporotic fracturespaget on diseasehypercalcaemia maligniteetti.

Euroopan unioni - suomi - EMA (European Medicines Agency)

pharming group n.v. - rekombinantti ihmisen c1-estäjä - angioedeema, perinnöllinen - drugs used in hereditary angioedema, other hematological agents - ruconest on tarkoitettu akuuttien angioödeemihyökkäysten hoitoon aikuisilla, joilla on perinnöllinen angioödeema (hae), johtuen c1-esteraasi-inhibiittorin puutoksesta.

Euroopan unioni - suomi - EMA (European Medicines Agency)

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - hevoseläinten immunologiset - hevoset - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.

Euroopan unioni - suomi - EMA (European Medicines Agency)

leti pharma, s.l.u. - recombinant protein q from leishmania infantum mon-1 - inaktivoidut bakteerirokotteet (kuten mykoplasma -, kurkkumätä-ja klamydia) - koirat - 6 kuukauden ikäisten koirien aktiivinen immunisointi leishmaniaasin kliinisen tapauksen riskin vähentämiseksi.

Euroopan unioni - suomi - EMA (European Medicines Agency)

glaxosmithkline biologicals sa - recombinant varicella zoster virus glycoprotein e - herpes zoster - rokotteet - shingrix is indicated for prevention of herpes zoster (hz) and post-herpetic neuralgia (phn), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of hz. käyttö shingrix pitäisi olla virallisten suositusten mukaisesti.